On February 3, 2022 Sprinter Health, an on-demand mobile health service bringing personalized and affordable healthcare services to the home, reported a collaboration with Naveris, a molecular diagnostics company dedicated to improving patient care through early detection of virus-related cancers (Press release, Naveris, FEB 3, 2022, View Source [SID1234607715]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The partnership will improve the detection, treatment, and clinical management of HPV-driven cancers, such as head and neck cancers, by augmenting the convenience of Naveris’ lead product, NavDx, which requires regular blood draws. Patients living in Sprinter Health service areas will be able to easily schedule a visit from a Sprinter Health nurse or phlebotomist (also known as "Sprinters") to collect blood specimens for the test in the comfort of their homes.
The NavDx blood test uses proprietary technology to detect circulating tumor tissue modified HPV (TTMV) DNA. NavDx helps healthcare providers optimize the clinical management of HPV-driven cancer by accurately assessing treatment response, identifying the presence of post-treatment molecular residual disease, and conveniently monitoring for recurrence. The test has been shown to accurately detect cancer recurrence a median of four months earlier than it would present clinically via PET or CT scan, which can facilitate earlier intervention of salvage therapy.1
"Patients being monitored with NavDx need regular blood draws, so we want to make sure they have a consistent, positive experience and don’t have to navigate a complex system just to get their blood specimens collected," said Piyush Gupta, CEO of Naveris. "Sprinter Health’s tech platform makes booking appointments easy for our patients and customer support reps, and they have become a partner we can count on to deliver high quality, reliable care that our patients love."
"Barriers to access can hold back progress toward better care. Lowering these barriers starts with using technology to improve the patient experience," said Max Cohen, CEO of Sprinter Health. "My father is an oncologist, and I’ve seen firsthand the difficult journeys of patients and families experiencing cancer. We’re proud to play a small part in helping patients access Naveris’ innovative test, and look forward to expanding our partnership throughout 2022."
Both companies have been working together in California for several months and plan to expand the partnership to new states in the first half of 2022.